Flurizan study released at ICAD

'Flurizan is a modified and safer form of a non-steroidal anti-inflammatory drug (like brufen), which in experimental studies seems to reduce deposits of the protein amyloid that is at the core of the plaques that develop in the brain in Alzheimer's disease. The study found that the drug Flurizan helped to slow the progression of Alzheimer's disease and that the effects of this drug were maximised with early and prolonged treatment. This is an important study which may offer hope to millions with Alzheimer's disease and we eagerly await the completion of ongoing larger studies.

We hope that the Government will put measures in place to assist the early diagnosis of Alzheimer's disease so that the proper benefits of this treatment and others can be received in future.'

Professor Clive Ballard
Director of research